{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:49:41Z","timestamp":1793663381249,"version":"4.5.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011404","name":"Indivior PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011404","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jsat.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T11:29:39Z","timestamp":1562930979000},"page":"148-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Buprenorphine in the United States: Motives for abuse, misuse, and diversion"],"prefix":"10.1016","volume":"104","author":[{"given":"Howard D.","family":"Chilcoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halle R.","family":"Amick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly R.","family":"Sherwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.07.005_bb0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2016.08.002","article-title":"Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma","volume":"70","author":"Allen","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.005_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1370\/afm.2099","article-title":"Barriers rural physicians face prescribing buprenorphine for opioid use disorder","volume":"15","author":"Andrilla","year":"2017","journal-title":"Annals of Family Medicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.07.005_bb0015","first-page":"S17","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"American Journal on Addictions"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ADM.0b013e3182034e31","article-title":"Illicit use of buprenorphine\/naloxone among injecting and noninjecting opioid users","volume":"5","author":"Bazazi","year":"2011","journal-title":"Journal of Addiction Medicine"},{"issue":"7","key":"10.1016\/j.jsat.2019.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2019.07.005_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1016\/j.jsat.2019.07.005_bb0035","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/15563650903438566","article-title":"2008 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report","volume":"47","author":"Bronstein","year":"2009","journal-title":"Clinical Toxicology (Philadelphia)"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pme.12295","article-title":"Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation","volume":"15","author":"Cassidy","year":"2014","journal-title":"Pain Medicine"},{"key":"10.1016\/j.jsat.2019.07.005_bb0045","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jsat.2019.07.005_bb0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","article-title":"Factors contributing to the rise of buprenorphine misuse: 2008\u20132013","volume":"142","author":"Cicero","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2019.07.005_bb0055","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/pds.1452","article-title":"Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States","volume":"16","author":"Cicero","year":"2007","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"6","key":"10.1016\/j.jsat.2019.07.005_bb0060","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5055\/jom.2007.0018","article-title":"Use and misuse of buprenorphine in the management of opioid addiction","volume":"3","author":"Cicero","year":"2007","journal-title":"Journal of Opioid Management"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/jpet.301.1.266","article-title":"Intravenous buprenorphine self-administration by detoxified heroin abusers","volume":"301","author":"Comer","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jsat.2019.07.005_bb0070","author":"Council of Economic Advisers, & Executive Office of the President of the United States"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.09.029","article-title":"Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids","volume":"122","author":"Daniulaityte","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.jsat.2019.07.005_bb0080","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1526-4637.2010.00877.x","article-title":"Post-marketing surveillance of methadone and buprenorphine in the United States","volume":"11","author":"Dasgupta","year":"2010","journal-title":"Pain Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.005_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: No easy fix to its social and economic determinants","volume":"108","author":"Dasgupta","year":"2018","journal-title":"American Journal of Public Health"},{"key":"10.1016\/j.jsat.2019.07.005_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.forsciint.2014.02.009","article-title":"Non-natural manners of death among users of illicit drugs: Substance findings","volume":"238","author":"Delaveris","year":"2014","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jsat.2019.07.005_bb0095","author":"Drug Enforcement Administration, U.S. Department of Justice"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0100","first-page":"37","article-title":"Update on the clinical use of buprenorphine: In opioid-related disorders","volume":"58","author":"Ducharme","year":"2012","journal-title":"Canadian Family Physician"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-010-1898-4","article-title":"Acute effects of intramuscular and sublingual buprenorphine and buprenorphine\/naloxone in non-dependent opioid abusers","volume":"211","author":"Duke","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"issue":"12","key":"10.1016\/j.jsat.2019.07.005_bb0110","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs. maintenance therapy for prescription opioid dependence: A randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"10","key":"10.1016\/j.jsat.2019.07.005_bb0115","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","article-title":"The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013","volume":"54","author":"Florence","year":"2016","journal-title":"Medical Care"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jsat.2014.07.015","article-title":"Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants","volume":"48","author":"Fox","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.07.005_bb0125","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.drugalcdep.2006.01.016","article-title":"Development of opioid formulations with limited diversion and abuse potential","volume":"83","author":"Fudala","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10550887.2014.950030","article-title":"Diffusion and diversion of suboxone: An exploration of illicit street opioid selling","volume":"33","author":"Furst","year":"2014","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.jsat.2019.07.005_bb0135","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1016\/j.addbeh.2013.08.008","article-title":"Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland","volume":"38","author":"Genberg","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2019.07.005_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2019.07.005_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.forsciint.2012.07.011","article-title":"Comparison of fatal poisonings by prescription opioids","volume":"222","author":"Hakkinen","year":"2012","journal-title":"Forensic Science International"},{"key":"10.1016\/j.jsat.2019.07.005_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren't physicians prescribing more buprenorphine","volume":"78","author":"Huhn","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2019.07.005_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2019.07.005_bb0160","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"American Journal of Public Health"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.005_bb0165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines","volume":"49","author":"Jones","year":"2015","journal-title":"American Journal of Preventive Medicine"},{"key":"10.1016\/j.jsat.2019.07.005_bb0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.pbb.2014.04.012","article-title":"The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users","volume":"122","author":"Jones","year":"2014","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"9358","key":"10.1016\/j.jsat.2019.07.005_bb0175","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0180","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","article-title":"American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use","volume":"9","author":"Kampman","year":"2015","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2019.07.005_bb0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.drugalcdep.2017.05.047","article-title":"Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances","volume":"178","author":"Kandel","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.07.005_bb0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","article-title":"The relationship between diversion-related attitudes and sharing and selling buprenorphine","volume":"78","author":"Kenney","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"Suppl. 1","key":"10.1016\/j.jsat.2019.07.005_bb0195","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.drugalcdep.2016.08.642","article-title":"Buprenorphine physician supply: Relationship with state-level prescription opioid mortality","volume":"173","author":"Knudsen","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.005_bb0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","article-title":"Statement of the American society of addiction medicine consensus panel on the use of buprenorphine in office-based treatment of opioid addiction","volume":"5","author":"Kraus","year":"2011","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of buprenorphine sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.07.005_bb0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addbeh.2019.01.023","article-title":"Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties","volume":"93","author":"Lin","year":"2019","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0215","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.drugalcdep.2012.05.025","article-title":"Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine","volume":"126","author":"Lofwall","year":"2012","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world","volume":"8","author":"Lofwall","year":"2014","journal-title":"Journal of Addictive Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2011.04.008","article-title":"Efficacy of continuing medical education to reduce the risk of buprenorphine diversion","volume":"41","author":"Lofwall","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jsat.2006.11.009","article-title":"Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients","volume":"33","author":"Maremmani","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.07.005_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2015.04.009","article-title":"Medicaid coverage of medications to treat alcohol and opioid dependence","volume":"55","author":"Mark","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0240","article-title":"The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales","volume":"5","author":"Marteau","year":"2015","journal-title":"British Medical Journal Open"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.005_bb0245","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology (Berlin)"},{"issue":"8","key":"10.1016\/j.jsat.2019.07.005_bb0255","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine\/naloxone tablets in opioid abusers","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0260","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/10550490903077820","article-title":"Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland","volume":"18","author":"Mitchell","year":"2009","journal-title":"American Journal on Addictions"},{"key":"10.1016\/j.jsat.2019.07.005_bb0265","first-page":"1","article-title":"Barriers to buprenorphine expansion in Ohio: A time-elapsed qualitative study","author":"Molfenter","year":"2019","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2019.07.005_bb0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2015.04.010","article-title":"Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention","volume":"57","author":"Monico","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0275","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550880903014767","article-title":"Diversion of buprenorphine\/naloxone coformulated tablets in a region with high prescribing prevalence","volume":"28","author":"Monte","year":"2009","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2019.07.005_bb0280","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.drugalcdep.2014.09.517","article-title":"The misuse, abuse and diversion of opioid replacement therapies (ORT): A study of street abusers","volume":"146","author":"Novak","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.005_bb0285","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0002-9343(98)00194-6","article-title":"A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic","volume":"105","author":"O'Connor","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0290","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","article-title":"Buprenorphine\/naloxone: A review of its use in the treatment of opioid dependence","volume":"69","author":"Orman","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jsat.2019.07.005_bb0295","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2015.08.007","article-title":"Buprenorphine infrequently found in fatal overdose in new York City","volume":"155","author":"Paone","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.07.005_bb0300","doi-asserted-by":"crossref","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"British Medical Journal"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0305","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/clpt.1993.72","article-title":"Subjective and physiologic effects of intravenous buprenorphine in humans","volume":"53","author":"Pickworth","year":"1993","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.005_bb0310","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/BF00212842","article-title":"Buprenorphine and naloxone alone and in combination in opioid-dependent humans","volume":"94","author":"Preston","year":"1988","journal-title":"Psychopharmacology (Berlin)"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0315","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1176\/ajp.155.3.447-b","article-title":"Six deaths linked to misuse of buprenorphine-benzodiazepine combinations","volume":"155","author":"Reynaud","year":"1998","journal-title":"American Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jsat.2010.03.014","article-title":"Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers","volume":"39","author":"Schuman-Olivier","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.jsat.2019.07.005_bb0325","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1521-0391.2013.12024.x","article-title":"Clinician beliefs and attitudes about buprenorphine\/naloxone diversion","volume":"22","author":"Schuman-Olivier","year":"2013","journal-title":"American Journal on Addictions"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2019.07.005_bb0330","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.forsciint.2012.03.016","article-title":"Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome","volume":"220","author":"Selden","year":"2012","journal-title":"Forensic Science International"},{"issue":"4","key":"10.1016\/j.jsat.2019.07.005_bb0335","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2014.2421","article-title":"The untapped potential of office-based buprenorphine treatment","volume":"72","author":"Sigmon","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.jsat.2019.07.005_bb0340","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.pain.2013.05.053","article-title":"Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations","volume":"154","author":"Smith","year":"2013","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.jsat.2019.07.005_bb0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5055\/jom.2013.0152","article-title":"Consumer attitudes about opioid addiction treatment: A focus group study in New York City","volume":"9","author":"Sohler","year":"2013","journal-title":"Journal of Opioid Management"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0350","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2014.07.010","article-title":"Supply of buprenorphine waivered physicians: The influence of state policies","volume":"48","author":"Stein","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0355","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/1468-0009.12137","article-title":"Where is buprenorphine dispensed to treat opioid use disorders? The role of private offices, opioid treatment programs, and substance abuse treatment facilities in urban and rural counties","volume":"93","author":"Stein","year":"2015","journal-title":"Milbank Quarterly"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0360","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jsat.2019.07.005_bb0365","author":"Substance Abuse and Mental Health Services Administration"},{"key":"10.1016\/j.jsat.2019.07.005_bb0370","series-title":"Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on drug use and health (HHS Publication No. SMA 17-5044, NSDUH series H-52)","author":"Substance Abuse and Mental Health Services Administration","year":"2017"},{"key":"10.1016\/j.jsat.2019.07.005_bb0375","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2017.10.002","article-title":"Prescribing patterns of buprenorphine waivered physicians","volume":"181","author":"Thomas","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0380","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: Partial agonist and blockade effects","volume":"274","author":"Walsh","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.jsat.2019.07.005_bb0385","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: Ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10550887.2011.642757","article-title":"The emerging buprenorphine epidemic in the United States","volume":"31","author":"Wish","year":"2012","journal-title":"Journal of Addictive Diseases"},{"issue":"3","key":"10.1016\/j.jsat.2019.07.005_bb0395","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1521-0391.2012.00335.x","article-title":"Steps physicians report taking to reduce diversion of buprenorphine","volume":"22","author":"Yang","year":"2013","journal-title":"American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2019.07.005_bb0400","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: An international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Current Drug Abuse Reviews"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547218304720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:56Z","timestamp":1760039456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547218304720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":80,"alternative-id":["S0740547218304720"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.07.005","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine in the United States: Motives for abuse, misuse, and diversion","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}